A Phase 2 interventional study of A. Desmopressin 10 microgram and B: Desmopressin 25 microgram in Nocturia, sponsored by Ferring Pharmaceuticals. Completed at 36 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-23.
Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment
The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult women during 12 weeks treatment
124 studies on the registry are indexed under Nocturia; 24 are open to participants now.
This study's enrollment of 178 is above the median of 67 across 94 interventional studies indexed under Nocturia.
Browse Nocturia studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: A. Desmopressin 10 microgram
Drug: B: Desmopressin 25 microgram
Drug: C: Placebo
1 orally disintegrating tablet every night during study period
1 orally disintegrating tablet every night during study period
1 orally disintegrating tablet every night during study period
Change from baseline in mean number of nocturnal voids
Time frame: During 12 weeks
Change from baseline in mean time to first void
Time frame: During 12 weeks
Responder status (33% reduction in nocturnal voids)
Time frame: During 12 weeks
Change from baseline in mean number of nocturnal voids
Time frame: 1, 4, 8 and 12 weeks
Change from baseline in mean time to first void
Time frame: 1, 4, 8 and 12 weeks
Responder status (33% reduction in nocturnal voids)
Time frame: 1, 4, 8 and 12 weeks
Change from baseline in mean nocturnal urine volume
Time frame: 1, 4, 8 and 12 weeks
Change from baseline in nocturnal polyuria index
Time frame: 1, 4, 8 and 12 weeks
Change from baseline in the effect on sleep disturbance
Time frame: 1, 4, 8 and 12 weeks
Change from baseline in the impact on quality of life
Time frame: 12 weeks
Adverse events, changes from baseline in serum sodium level, laboratory values
Time frame: During 12 weeks
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals